CHILDREN'S CANCER STUDY GROUP

加州大学儿科血液科-肿瘤科 密歇根州在儿童癌症的所有开放研究中进行合作 学习小组，以改善护理和生存为目标 患有癌症的儿童。该科有六名全职诊所。 在牛津大学担任教职的调查人员 密歇根医学院，以及一个积极的奖学金计划 在儿科血液肿瘤学中与三名研究员一起接受培训 一年三年。在100到150名新患者之间 被诊断的癌症在我们的部门登记在CCSG Per 年。参加CCSG治疗研究的患者数量 在过去的三年里，每年都有超过80名患者。在……里面 此外，我们目前正在跟踪393名患者，他们的 需要提交CCSG研究数据。此外， 密歇根大学患者治疗研究招生报告 是公开招收患者的机构领导者之一 流行病学研究和其他专门研究，如 急性淋巴细胞白血病治疗患者的神经生理功能评估 CCG-105NP与口腔维持性药物的药理吸收 全部(CCG-105PH)。此外，密歇根大学是其中之一 参与第一阶段的CCSG机构的子集 临床试验。 共有10名多学科调查人员组成了委员会 预约。两个人是四个治疗师的主席 研究委员会，每个委员会监督一项重大临床试验。Dr。 哈钦森将担任校长一职 研究员是开放的CCG-521高级研究的主席 霍奇金氏病与建议的CG-1001(CCG-164)研究 适用于低风险ALL患者。海恩博士是两家公司的董事长。 CCG-984研究中的组织细胞增多症-X和 CCG-681关于CCSG参与集团间的研究 横纹肌肉瘤研究II。此外，Hutchinson博士还担任 CCSG Hodgkin的研究协调员。哈钦森医生目前 探索开放他的机构研究的可能性 放射性标记间碘苯甲基胍治疗肺癌的疗效观察 神经母细胞瘤患者加入CCSG。哈纳什博士是 与癌症生物学委员会成员和 白血病诊断委员会关于使用他的两个- 用于白血病分析的三维凝胶电泳法 急性淋巴细胞白血病患者CCSG研究中的细胞蛋白。博士 McKeever，一位神经病理学家，CCG-961研究的成员 委员会，正在开发一项针对神经病理的CCSG研究 低级别星形细胞瘤的预后因素。沃斯克维茨女士和 伦纳德夫人，两位护士临床医生，将继续他们的 在CCSG护理委员会和其他几个委员会中的积极作用 学习委员会。此外，密歇根大学计划 继续其先前对CCSG所有活动的大力支持。

The Division of Pediatric Hematology-Oncology of the University of Michigan collaborates in all open studies of the Children's Cancer Study Group, with the goal of improving the care and the survival of children with cancer. The Division has six full-time clinical investigators with faculty appointments at the University of Michigan Medical School, as well as an active fellowship program in pediatric hematology-oncology with three fellows in training per year for three years. Between 100 and 150 patients with newly diagnosed cancer are registered from our Division with CCSG per year. The number of patients entered on CCSG therapeutic studies has exceeded 80 patients for each of the last three years. In addition, we are currently following 393 patients for whom the submission of CCSG study data is required. In addition, to therapeutic study enrollment of patients the University of Michigan is among the institutional leaders in enrolling patients on open epidemiological studies and on other special studies such as those assessing neurophyschologic function in patients treated for ALL (CCG-105NP) and pharmacologic absorption of oral maintenance drugs in ALL (CCG-105PH). Furthermore, the University of Michigan is one of a subset of CCSG institutions which participate in phase I clinical trials. A total of 10 multidisciplinary investigators have committee appointments. Two individuals are the chairmen of four therapeutic study committees, each overseeing a major clinical trial. Dr. Hutchinson who will be assuming the position of principal investigator is chairman of the open CCG-521 Study for advanced Hodgkin's disease and the CG-1001 (CCG-164) Study which is proposed for patients with low-risk ALL. Dr. Heyn is chairman of two studies now in follow-up the CCG-984 Study for histiocytosis-X and the CCG-681 Study for CCSG participation in the Intergroup Rhabdomyosarcoma Study II. In addition, Dr. Hutchinson serves as coordinator of CCSG Hodgkin's studies. Dr. Hutchinson is presently exploring the possibility of opening his institutional study of the therapeutic efficacy or radiolabelled metaiodobenzylguanidine for patients with neuroblastoma to CCSG participation. Dr. Hanash is collaborating with members of the Cancer Biology Committee and the Leukemia Diagnosis Committee relative to the use of his two- dimensional gel electrophoretic technique for analysis of leukemic cellular proteins in CCSG studies of patients with ALL. Dr McKeever, a neuropathologist and member of the CCG-961 Study Committee, is developing a CCSG study addressing neuropathologic prognostic factors in low grade astrocytomas. Ms. Waskerwitz and Mrs. Leonard, the two nurse clinicians, will continue their very active roles within the CCSG Nursing Committee and on several other study committees. Furthermore, the University of Michigan plans to continue its prior strong support of all CCSG activities.